Table 1.
Characteristic | POLE EDMs | POLE wild-type and POLE non-EDMs | P value |
Total | 9 (3.1) | 286 (96.9) | -- |
Age (IQR) | 46 (43–54) | 62 (54–71) | <0.001 |
Gender | 0.162 | ||
Female | 2 (22.2) | 131 (45.8) | |
Male | 7 (77.8) | 155 (54.2) | |
Histological type | 0.196 | ||
Adenocarcinoma | 6 (66.7) | 238 (83.2) | |
Mucinous adenocarcinoma | 3 (33.3) | 48 (16.8) | |
Pathological grade | 0.372 | ||
Well | 0 (0) | 18 (6.3) | |
Moderate | 5 (55.6) | 200 (69.9) | |
Poor | 3 (33.3) | 59 (20.6) | |
Unknown | 1 (11.1) | 9 (3.2) | |
Location | 0.003 | ||
Right | 6 (66.7) | 66 (23.1) | |
Left | 3 (33.3) | 220 (76.9) | |
pT stage | 0.832 | ||
T3 | 5 (55.6) | 169 (59.1) | |
T4 | 4 (44.4) | 117 (40.9) | |
LNH | 0.498 | ||
<12 | 1 (11.1) | 58 (20.3) | |
≥12 | 8 (88.9) | 228 (79.7) | |
Lymphovascular invasion | 0.003 | ||
Negative | 4 (44.4) | 237 (82.9) | |
Positive | 5 (55.6) | 49 (17.1) | |
Perineural invasion | 0.264 | ||
Negative | 8 (88.9) | 206 (72.0) | |
Positive | 1 (11.1) | 80 (28.0) | |
Pretreatment CEA | 0.541 | ||
Negative | 8 (88.9) | 231 (80.8) | |
Positive | 1 (11.1) | 55 (19.2) | |
Chemotherapy | 0.663 | ||
No | 3 (33.3) | 116 (40.6) | |
Yes | 6 (66.7) | 170 (59.4) | |
MSI status | 0.043 | ||
MSS | 6 (66.7) | 254 (88.8) | |
MSI-H | 3 (33.3) | 32 (11.2) | |
RAS | 0.109 | ||
Wild-type | 2 (22.2) | 141 (49.3) | |
Mutation | 7 (77.8) | 145 (50.7) | |
BRAF | 0.116 | ||
Wild-type | 7 (77.8) | 264 (92.3) | |
Mutation | 2 (22.2) | 22 (7.7) | |
PTEN | <0.001 | ||
Wild-type | 3 (33.3) | 265 (92.7) | |
Mutation | 6 (66.7) | 21 (7.3) | |
PIK3CA | <0.001 | ||
Wild-type | 1 (11.1) | 227 (79.4) | |
Mutation | 8 (88.9) | 59 (20.6) |
CEA, carcinoembryonic antigen; CRC, colorectal cancer; EDM, exonuclease domain mutation; FUSCC, Fudan University Shanghai Cancer Center; LNH, lymph nodes harvested; MSI-H, microsatellite instability-high; MSS, microsatellite stabilization.